Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

GU Cancers 2018 and Treatment View overview page

1:08
Research highlights in nmCRPC: PROSPER and SPARTAN studies
Andrew Armstrong • 8 Feb 2018
1:45
Targeting plasticity pathways for novel therapy in prostate cancer
Andrew Armstrong • 8 Feb 2018
2:16
The agents at the forefront of kidney cancer treatment
Michael Atkins • 8 Feb 2018
3:32
Debating the future of prostate cancer management
Francesco Montorsi • 8 Feb 2018
1:37
The impact of PSA in prostate cancer and its limitations
Francesco Montorsi • 8 Feb 2018
3:11
Novel drugs for patients with renal cell carcinoma
Francesco Montorsi • 8 Feb 2018
1:31
Combining immunotherapy with VEGF inhibitors to treat kidney cancer
Michael Atkins • 8 Feb 2018
3:30
Promising results for axitinib and pembrolizumab in advanced renal cell cancer
Michael Atkins • 8 Feb 2018
3:23
FALCON: radiopharmaceuticals for the management of recurrent prostate cancer
Eugene Teoh • 8 Feb 2018
2:00
Future therapy options for muscle-invasive bladder cancer
Jeanny Aragon-Ching • 8 Feb 2018
3:04
Success of novel immunotherapies for renal cell carcinoma
Jeanny Aragon-Ching • 8 Feb 2018
2:48
Using biomarkers to identify bladder cancer patients for neoadjuvant therapy
Peter Black • 8 Feb 2018
1:52
Can atezolizumab succeed where BCG fails in bladder cancer?
Peter Black • 8 Feb 2018
1:08
Systemic treatments for non-muscle invasive bladder cancer
Peter Black • 8 Feb 2018
2:59
Immunotherapy for prostate, bladder and kidney cancer
Elizabeth Plimack • 8 Feb 2018
1:06
Exciting potential of pembrolizumab combined with axitinib for kidney cancer
Elizabeth Plimack • 8 Feb 2018
The content of VJOncology is intended for healthcare professionals